Streetwise Articles


News Update

Cell Therapy Company and Chinese Firm Sign Marketing Deal

  ()
This biotech, in Phase 1 development of regenerative technologies addressing skin and orthopedic indications, has finalized a commercialization deal with YOFOTO. read more >
News Update

Preclinical Data for Alzheimer's Therapy to Be Presented at AAIC

  ()
A poster outlining data from this company's lead candidate, which targets toxic oligomers identified as a potential cause of Alzheimer's disease, will be presented at the Alzheimer's Association International Conference (AAIC). read more >

Three Companies Poised to Benefit from Proposed Medicare Home Health Monitoring Change

  ()
A proposed rule change would allow Medicare to reimburse home health agencies for remote patient monitoring, providing an opportunity for health technology companies. read more >

Study Shows Biopharma's Lead Drug Mediates T Cell Tumor Infiltration

Research Report
  ()
An Echelon Wealth Partners report discussed this firm's stock performance and how a recent clinical trial update impacted it. read more >

Coverage Initiated on 'True Original' Using RNAi to Enhance Cancer Immunotherapy

Research Report
  ()
An H.C. Wainwright & Co. report outlined the thesis for investing in this emerging biotech. read more >

Target Price Increased on Biotech After Q2/18 Revenue Record, Beat

Research Report
  ()
A Maxim Group report explained the likely reasons behind revenue growth for the firm, which produces media used in development of cell therapies. read more >

EpiPen Rival Lands Major Partner

Research Report
  ()
An H.C. Wainwright & Co. report explains the deal, which concerns a new single-dose epinephrine injection for severe allergic reactions. read more >

Coverage Initiated on Biopharma with 'Opioid Sparing Solution for Post-Op Pain'

Research Report
  ()
An H.C. Wainwright & Co. report highlighted the advantages, status and potential of this lead asset. read more >

Immunotherapy Firm's Triple Combination Trial for Glioblastoma Sees First Patient Dosed

Research Report
  ()
A Maxim Group note discussed the latest clinical endeavor involving a three-pronged approach targeting glioblastoma. read more >
Breaking News

Candidates Targeting Parkinson's Disease and ALS Advance in Discovery Phase

  ()
This precision medicine company, focused on neurodegenerative diseases, has selected antibody candidates to advance into the final phase of discovery. read more >

Agreement Facilitates Progress Toward Medical Device Approvals

  ()
This medical device company enters a partnership to provide quality and regulatory services. read more >

Transfusion Medicine Biotech Hits Target on Road to Commercialization

Research Report
  ()
A BTIG report reviewed the news announced by this supplier of blood grouping reagents and control products. read more >

Coverage Initiated on Immunotherapy Developer with Phase 3 Lead Asset

Research Report
  ()
A B. Riley FBR report provided an overview of this life sciences firm. read more >

Biotech Releases 'Unequivocally Positive' Topline NASH Study Results

Research Report
  ()
An H.C. Wainwright & Co. report relayed the highlights of the new trial data from this Israel-based firm. read more >
News Update

Biotech Targeting Alzheimer's Disease Advances Toward Phase 1

  ()
Having secured a manufacturing partner for its proprietary antibody candidate, this precision medicine company charts progress toward a Phase 1 trial in Alzheimer's disease. read more >

Mobile Health Platform Firm Signs Deal That Will Increase Pace of Onboarding Patients

  ()
A technology company that develops mobile health and telemedicine platforms for community-based healthcare has raised money, made a deal that will accelerate the number of patients it adds every month, and is breaking through its hardware logjam. read more >

Biotech Consolidates Shares in Preparation for NASDAQ Listing

Research Report
  ()
A Canaccord Genuity analyst provided an update on this late-stage Canadian life sciences firm targeting metastatic breast cancer. read more >

Coverage Initiated on Developer of Women's Reproductive Health Products

Research Report
  ()
A ROTH Capital Partners research report outlined the key drivers of the investment thesis for this firm. read more >

Biotech Announces Encouraging HIV Vaccine Results

Research Report
  ()
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained the recently released data from a study of one of this immunotherapy firm's therapeutics. read more >

Analyst: 'New CEO, Larger Sales Team and Greater SUI Focus Should Help Medical Device Growth'

Research Report
  ()
Cowen analyst Dr. Joshua Jennings highlighted this medical device firmís Q1/18 developments and financial results. read more >
Management Q&A: View from the Top

Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way

Managment Q&A: View from the Top
  ()
In this interview with The Life Sciences Report, IMV Inc.'s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of the company, and holds long-term promise for cancer patients. read more >

Biotech's Launch of Pain Product Shows Encouraging Early Metrics

Research Report
  ()
Francois Brisebois, an analyst with Laidlaw & Co., reviewed this firm's progress since commercially debuting its primary asset. read more >

Concurrent Milestones for Biotech Set to Occur 'on the Horizon'

Research Report
  ()
Analyst Douglas Loe with Echelon Wealth Partners discussed this immunotherapy developer's recent and upcoming news. read more >

Cell Therapy Firm Finalizing $5.1M Strategic Investment and Partnership with Chinese Company

  ()
The terms of a proposed agreement between this cell therapy company and YOFOTO, a Chinese health and consumer products company, have been revised and will result in a $5.1 million investment. read more >

What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease

  ()
In the second of a two-part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small-cap companies targeting big-ticket indications and their potential to drive blockbuster value for both patients and investors. read more >
Showing Results: 1 to 25 of 62 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"We are initiating coverage on PMN."
– John Vandermosten, Zacks Small-Cap Research